Glaukos Stock (NYSE:GKOS), Trade Ideas

Glaukos

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ALTM

ATAI

CALM

DXYZ

ESPR

GKOS

OCGN

PLAY

PRCH

PYXS

RILY

SLCA

SMTC

SMXT

SPOT

TMDX

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

Signet Jewelers, Dave &amp; Buster&#39;s Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

Price Target

Pre-Market Outlook

Analyst Ratings

AUPH

COTY

CRSP

JACK

ROOT

UCTT

WING

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Analyst Color

Long Ideas

Upgrades

Health Care

General

Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.

Glaukos&#39; Newly Approved Glaucoma Treatment Is The &#39;Biggest Driver To Watch&#39;: Analyst

Glaukos Corp

Mizuho analyst Anthony Petrone maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Neutral and raises the price target from $85 to $100.

Mizuho Maintains Neutral on Glaukos, Raises Price Target to $100

In the last three months, 7 analysts have published ratings on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $109.43, along with a high estimate of $120.00 and a low estimate of $103.00. Surpassing the previous average price target of $101.25, the current average has increased by 8.08%.
<img src="https://www.benzinga.com/files/images/story/2024/1712592052_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Glaukos by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Glaukos's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>A Deep Dive into Glaukos's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Glaukos showcased positive performance, achieving a revenue growth rate of 15.64% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -44.65%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -7.83%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Glaukos's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.83, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Glaukos

Truist Securities analyst Samuel Brodovsky reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and maintains $110 price target.

Reiteration

Truist Securities Reiterates Buy on Glaukos, Maintains $110 Price Target

WIIM

Glaukos shares are trading higher after the US Centers for Medicare and Medicaid Services assigned a permanent J-code for iDose TR.

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Shares of Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) rose sharply during Wednesday&rsquo;s session after the company <a href="https://www.benzinga.com/markets/equities/24/04/38068195/whats-going-on-with-signet-jewelers-stock-today">raised its FY25 guidance.</a>
The company and Leonard Green &amp; Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. 
Signet increased its FY25 adjusted EPS outlook to $9.90 &ndash; $11.52 from $9.08 &ndash; $10.48 versus an estimate of $9.72.
Signet Jewelers shares surged 9.2% to $103.80 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) shares jumped 21.4% to $25.77.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) shares gained 14.2% to $1.5750. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterated Ocugen with a Buy and maintained a $7 price target.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) rose 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) climbed 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) rose 10.4% to $11.85.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares gained 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) gained 9.7% to $3.16.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) rose 9.2% to $79.47.</li>
<li>Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) gained 8.3% to $4.3450. Cantor Fitzgerald analyst Josh Siegler maintained Porch Group with an Overweight and raised the price target from $3 to $5.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) gained 7.7% to $10.95.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) climbed 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) shares gained 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
<li>Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) rose 6.8% to $95.59. Glaukos received permanent J-code for iDose&reg; TR (travoprost intracameral implant).</li>
<li>Blue Owl Capital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/owl#NYSE">OWL</a>) gained 6.4% to $19.69 after the company announced a purchase agreement to acquire Kuvare Insurance Services LP for $750 million.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) rose 6.3% to $23.88.</li>
<li>U.S. Silica Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slca#NYSE">SLCA</a>) gained 6.2% to $13.47.</li>
<li>Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) rose 5.6% to $284.61 on reports the company will raise monthly prices.</li>
<li>Arcadium Lithium plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/altm#NASDAQ">ALTM</a>) gained 4.8% to $4.34. Raymond James upgraded the stock from Outperform to Strong Buy and maintained its $9 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38062892/how-to-earn-500-a-month-from-levi-strauss-stock-ahead-of-q1-earnings-report"> How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q1 Earnings Report</a>

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

Stifel analyst Thomas Stephan reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and maintains $110 price target.

Stifel Reiterates Buy on Glaukos, Maintains $110 Price Target

U.S. Centers For Medicare And Medicaid Services Has Assigned Unique, Permanent Healthcare Common Procedure Coding System J-code For Glaukos' iDose TR (Travoprost Intracameral Implant) 75 mcg  For Reduction Of Intraocular Pressure

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $107 to $120.

Citigroup Maintains Buy on Glaukos, Raises Price Target to $120

In the last three months, 5 analysts have published ratings on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $105.2, along with a high estimate of $110.00 and a low estimate of $100.00. This current average has increased by 9.58% from the previous average price target of $96.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1711134079_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Glaukos's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>Delving into Glaukos's Background</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Understanding the Numbers: Glaukos's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Glaukos showcased positive performance, achieving a revenue growth rate of 15.64% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -44.65%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -7.83%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.89%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.83, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Glaukos

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised the price target for Wix.com Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wix#NASDAQ">WIX</a>) from $146 to $165. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Wix.com shares rose 5.9% to close at $132.77 on Thursday. <a href="https://www.benzinga.com/quote/WIX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted Analog Devices, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adi#NASDAQ">ADI</a>) price target from $220 to $230. Keybanc analyst John Vinh maintained an Overweight rating. Analog Devices shares gained 2.3% to close at $193.72 on Wednesday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) from $105 to $108. Needham analyst David Saxon maintained a Buy rating. Glaukos shares rose 0.7% to close at $92.79 on Wednesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised Wingstop Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wing#NASDAQ">WING</a>) price target from $295 to $355. TD Cowen analyst Andrew Charles maintained an Outperform rating. Wingstop shares fell 4.4% to close at $310.32 on Wednesday. <a href="https://www.benzinga.com/quote/WING/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital increased the price target for CRISPR Therapeutics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crsp#NASDAQ">CRSP</a>) from $110 to $112. Chardan Capital analyst Geulah Livshits maintained a Buy rating. CRISPR Therapeutics shares gained 4.7% to close at $82.41 on Wednesday. <a href="https://www.benzinga.com/quote/CRSP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush cut the price target for Jack in the Box Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jack#NASDAQ">JACK</a>) from $83 to $79. Wedbush analyst Nick Setyan maintained a Neutral rating. Jack in the Box shares gained 0.3% to close at $73.95 on Wednesday. <a href="https://www.benzinga.com/quote/JACK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Aurinia Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auph#NASDAQ">AUPH</a>) price target from $15 to $13. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. Aurinia Pharmaceuticals shares gained 2.7% to close at $5.74 on Wednesday. <a href="https://www.benzinga.com/quote/AUPH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen increased Coty Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coty#NYSE">COTY</a>) price target from $13 to $16. TD Cowen analyst Oliver Chen upgraded the stock from Market Perform to Outperform. Coty shares gained 3.9% to close at $12.64 on Wednesday. <a href="https://www.benzinga.com/quote/COTY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted Ultra Clean Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uctt#NASDAQ">UCTT</a>) price target from $46 to $50. Needham analyst Charles Shi maintained a Buy rating. Ultra Clean shares gained 1% to close at $42.21 on Wednesday. <a href="https://www.benzinga.com/quote/UCTT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) price target from $9 to $13. H Cantor Fitzgerald analyst Josh Siegler upgraded the stock from Neutral to Overweight. Root shares fell 4.4% to close at $8.67 on Wednesday. <a href="https://www.benzinga.com/quote/ROOT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37253951/nvidia-keurig-dr-pepper-and-3-stocks-to-watch-heading-into-thursday"> NVIDIA, Keurig Dr Pepper And 3 Stocks To Watch Heading Into Thursday </a>

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $105 to $108.

Needham Maintains Buy on Glaukos, Raises Price Target to $108

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported its Q4 earnings results on Wednesday, February 21, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Glaukos missed estimated earnings by 14.55%, reporting an EPS of $-0.63 versus an estimate of $-0.55.
Revenue was up $11.14 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.05 which was followed by a 7.58% drop in the share price the next day.
Here's a look at Glaukos's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.55</td>
<td>-0.57</td>
<td>-0.57</td>
<td>-0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.50</td>
<td>-0.55</td>
<td>-0.59</td>
<td>-0.53</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>75.25M</td>
<td>74.46M</td>
<td>67.72M</td>
<td>68.01M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>78.05M</td>
<td>80.40M</td>
<td>73.90M</td>
<td>71.23M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Glaukos <a href="https://www.benzinga.com/quote/GKOS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Glaukos: Q4 Earnings Insights

Guidance

Glaukos Reaffirms 2024 Net Sales Guidance Of $350M-$360M, Est $356.29M

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported quarterly Adj losses of $(0.63) per share which missed the analyst consensus estimate of $(0.55) by 14.55 percent. This is a 18.87 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $82.36 million which beat the analyst consensus estimate of $78.69 million by 4.67 percent. This is a 15.64 percent increase over sales of $71.23 million the same period last year.

Glaukos Q4 Adj EPS $(0.63) Misses $(0.55) Estimate, Sales $82.36M Beat $78.69M Estimate

ACVA

ALIT

AMSF

ANSS

ATNI

BALY

BELFA

BELFB

BLCO

BRDG

BROS

BRSP

CAKE

CCAP

CCRN

CCSI

CENX

CHDN

CHRD

CNNE

COKE

CSTE

CSTM

DINO

DOCN

ECPG

ERII

ESEA

ETSY

EXAS

FIVN

GATO

GLBE

GOOD

GRMN

GSHD

ICLR

INSG

IONS

JOBY

KALU

LANV

LCID

LIVN

LUNG

MATV

MGRC

MTLS

NDSN

NEXA

NGVT

NOVA

NVDA

NVRO

NYMT

OBDC

Earnings Scheduled For February 21, 2024

In the preceding three months, 7 analysts have released ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Glaukos, presenting an average target of $93.43, a high estimate of $105.00, and a low estimate of $65.00. This current average has increased by 8.64% from the previous average price target of $86.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708084856_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Glaukos among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$88.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Glaukos. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Glaukos's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>All You Need to Know About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Understanding the Numbers: Glaukos's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 9.51%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -39.01%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Glaukos's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.8, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Needham analyst David Saxon reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and maintains $105 price target.

Needham Reiterates Buy on Glaukos, Maintains $105 Price Target

Glaukos shares are trading higher after the company reported preliminary Q4 and FY23 net sales guidance above estimates. Also, the company reaffirmed its FY24 net sales guidance.

Glaukos Reaffirms FY24 Net Sales Guidance Range Of $350M-$360M Versus Consensus Of $354.59M

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exact Sciences (EXAS – Research Report), Moderna (MRNA – Research...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)

Glaukos Corp (GKOS) is near the top in its industry group according to InvestorsObserver. GKOS gets an overall rating of 61. That means it scores higher than 61 percent of stocks. Glaukos Corp gets a 84 rank in the Medical Devices industry. Medical Devices is number 67 out of 148 industries. GKOS has an Overall Score of 61

Where Does Glaukos Corp (GKOS) Stock Fall in the Medical Devices Field After It Has Fallen -6.15% This Week?

Anthony Petrone, an analyst from Mizuho Securities, maintained the Hold rating on Glaukos (GKOS – Research Report). The associated price target is ...

Glaukos Corporation: Hold Rating with Cautious Optimism Amidst iDose Launch and Reimbursement Uncertainties

Citi screens for 25 stocks with growth capex opportunity

In a report released today, Samuel Brodovsky from Truist Financial maintained a Buy rating on Glaukos (GKOS – Research Report). The company's share...

Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), Bea...

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report), Glaukos (G...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)

In a report released today, Thomas Stephan from Stifel Nicolaus maintained a Buy rating on Glaukos (GKOS – Research Report), with a price target of...

Glaukos (GKOS) Gets a Buy from Stifel Nicolaus

Glaukos gains on permanent J-code for iDose TR

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

AMZN

AORT

ATEC

ATRC

AZTA

BEAM

CNMD

DLTR

ENOV

EQIX

EXEL

GOOGL

IRTC

ISRG

ITOT

KIDS

MRNA

NARI

OMCL

RXST

RYTM

SIBN

SMPL

SPTM

SRDX

STLD

VCYT

XRAY

Press Releases

Glaukos Announces Participation in Stifel Healthcare Conference

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1